Hugh M. Cole
Net Worth

Last updated:

What is Hugh M. Cole net worth?

The estimated net worth of Mr. Hugh M. Cole is at least $4,862,057 as of 10 Jan 2023. He has earned $372,747 from insider trading and has received compensation worth at least $4,489,310 in Jounce Therapeutics, Inc..

What is the salary of Hugh M. Cole?

Mr. Hugh M. Cole salary is $641,330 per year as Chief Bus. Officer & Head of Corporation Devel. in Jounce Therapeutics, Inc..

How old is Hugh M. Cole?

Mr. Hugh M. Cole is 60 years old, born in 1965.

What stocks does Hugh M. Cole currently own?

As insider, Mr. Hugh M. Cole owns shares in one company:

Company Title Shares Price per share Total value
Jounce Therapeutics, Inc. (JNCE) Chief Bus. Officer & Head of Corporation Devel. 110,082 $0 $0

What does Jounce Therapeutics, Inc. do?

Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. It is also developing JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; JTX -1484 for myeloid; and JTX-1811, an anti-CCR8 monoclonal antibody designed to selectively deplete intra-tumoral T regulatory cells in the tumor microenvironment. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.

JNCE logo
JNCE
Jounce Therapeutics, Inc.

Hugh M. Cole insider trading

Jounce Therapeutics, Inc.

Mr. Hugh M. Cole has made 14 insider trades between 2018-2023, according to the Form 4 filled with the SEC. Most recently he sold 9,182 units of JNCE stock worth $10,284 on 10 Jan 2023.

The largest trade he's ever made was exercising 18,000 units of JNCE stock on 22 Jan 2021. As of 10 Jan 2023 he still owns at least 110,082 units of JNCE stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock 9,182 $1.12 $10,284
Sale
Common Stock 7,452 $1.1 $8,197
Sale
Common Stock 6,205 $6.65 $41,263
Sale
Common Stock 3,468 $7.3 $25,316
Option
Stock Option (Right to Buy) 10,000 N/A N/A
Option
Common Stock 10,000 $4.4 $44,000
Sale
Common Stock 18,000 $11.95 $215,100
Sale
Common Stock 3,340 $7 $23,380
Sale
Common Stock 2,879 $6.76 $19,462
Sale
Common Stock 744 N/A N/A
Sale
Common Stock 454 N/A N/A
Sale
Common Stock 984 N/A N/A
Sale
Common Stock 2,624 $7.78 $20,415
Sale
Common Stock 1,018 $3.92 $3,991
Sale
Common Stock 648 $4 $2,592
Sale
Common Stock 670 $4.1 $2,747
Purchase
Common Stock 1,900 $7.84 $14,896

Jounce Therapeutics key executives

Jounce Therapeutics, Inc. executives and other stock owners filed with the SEC:

  • Dr. Richard Murray (66) Pres, Chief Executive Officer & Director
  • Mr. Hugh M. Cole (60) Chief Bus. Officer & Head of Corporation Devel.
  • Ms. Kimberlee Cobleigh Drapkin CPA, CPA (57) Chief Financial Officer & Treasurer